How do you pay?

How to pay the least

Ask for the cash price

Stivarga

We didn’t find one.

  1. Ask your pharmacy for Stivarga’s cash price, and one or two other pharmacies too.
  2. Stivarga’s savings card works only with insurance from a job or one you bought.

Free from the maker, if you qualify Bayer US Patient Assistance Foundation. Effective January 1, 2025, the financial eligibility requirement is 300% Federal Poverty Limit (FPL) for most Bayer prescription medications. Or call 1-866-228-7723.

See if you qualify 

Compare every option

Question
Brand nameStivarga
Authorized genericregorafenib
Regular genericregorafenib
What you’d pay
Cash priceAsk the pharmacy
Not soldThere isn’t one
Not soldNone found
Same as Stivarga?
The original
–
–

Brand nameThe maker’s card

STIVARGA $0 Co-Pay Program

Savings card from Bayer

No insuranceNeeds insuranceNo cash price listed.
Insurance · as little as $0 a month

Sign up on stivarga-us.com 

Or call 1-800-288-8374.

In the maker’s words

“Eligible commercially insured patients may pay as little as $0 per month…”

From the maker’s offer on stivarga-us.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Maker’s card or discount card?

A discount card like GoodRx lowers the pharmacy’s cash price, but for a brand-name drug that price often stays high. Compare it with the maker’s card above. You can usually use one or the other on a fill, not both.

Authorized genericNot sold

There isn’t one. An authorized generic is Stivarga itself, from the same company, sold without the brand name, and usually for less. For now Stivarga is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

We didn’t find one. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

What the FDA label says

STIVARGA is a kinase inhibitor indicated for the treatment of adult patients with:

  • Metastatic colorectal cancer (CRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type, an anti-EGFR therapy.
  • Locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.
  • Hepatocellular carcinoma (HCC) who have been previously treated with sorafenib

Source: the FDA label for Stivarga (Bayer HealthCare Pharmaceuticals Inc.), February 9, 2026. Full label on DailyMed 

Good to know